Post by Medical Device Network

Edwards Lifesciences has lifted its full-year 2026 growth outlook to between 9% and 11%, up from 8% to 10% previously, due to ‘better than expected’ performance in Q1. The medtech giant reported revenues of around $1.65bn in Q1, driven by steady double-digit growth across its portfolio. With the percentage uplift for the full year, Edwards now anticipates sales of $6.5bn to $6.9bn, with earnings mooted to fall in the $2.95 to $3.05 per share range, up from $2.90 to $3.05 previously. Edwards released its Q1 results after the market closed on 23 April. The company’s shares on the New York Stock Exchange (NYSE), correct as at 12pm BST on 24 April, were up by over 2% at $81.51, versus $79.72 at market close on the prior day. Bernard Zovighian, Edwards’ CEO, commented: “Building on a year in 2025 marked by solid financial performance and strategic progress, we delivered another strong quarter in Q1, achieving 12.7% sales growth, which reflects the impact and durability of our focused strategy. We remain dedicated to solving large, urgent and complex patient needs and pursuing unique opportunities to innovate and lead in structural heart disease.” #medtech #TAVR Read the full report below: https://lnkd.in/ePR3v78h